"10.1371_journal.pone.0139659","plos one","2015-10-13T00:00:00Z","Helle H Nielsen; Hans C Beck; Lars P Kristensen; Mark Burton; Tunde Csepany; Magdolna Simo; Peter Dioszeghy; Tobias Sejbaek; Manuela Grebing; Niels H H Heegaard; Zsolt Illes","Department of Neurology, Odense University Hospital, Odense, Denmark; Institute for Clinical Research, University of Southern Denmark, Odense, Denmark; Center for Clinical Proteomics, Odense University Hospital, Odense, Denmark; Department for Clinical Genetics Odense University Hospital, Odense, Denmark; Department of Neurology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary; Department of Neurology, Semmelweis University, Budapest, Hungary; Department of Neurology, Josa Andras Teaching Hospital, Nyiregyhaza, Hungary; Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark; Department of Autoimmunology & Biomarkers, Statens Serum Institut, Copenhagen, Denmark; Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark","Conceived and designed the experiments: HHN ZI. Performed the experiments: HCB LPK NHHH. Analyzed the data: HHN HCB LPK MB NHHH ZI. Contributed reagents/materials/analysis tools: HHN TC MS PD TS MG ZI. Wrote the paper: HHN HCB LPK MB TC MS PD TS MG NHHH ZI.","Helle H. Nielsen has received travel funding and speaker honoraria from and served on advisory boards for Merck-Serono, Novartis Healthcare, Biogen Idec, Genzyme Denmark, Teva Denmark and UCB Nordic. Hans C. Beck declares no potential conflicts of interest. Lars P. Kristensen declares no potential conflicts of interest. Mark Burton has nothing to declare. Tunde Csepany has received speaker honoraria/congress expense compensations from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Teva. Magdolna Simo has received compensation for consulting services and speaking from Biogen Idec, Merck‚ÄSerono, Novartis, Sanofi‚ÄAventis, and Teva Pharmaceutical Industries Ltd. Peter Dioszeghy has received compensation for consulting services from Biogen, Novartis, and Teva Pharmaceutical Industries Ltd. Tobias Sejb√¶k has received travel funding and speaker honoraria from Merck-Serono, Novartis Healthcare, Biogen Idec, Genzyme Denmark and Teva Denmark. Manuela Grebing declares no potential conflicts of interest. Niels H. H. Heegaard declare no conflicts of interest. Zsolt Illes has received compensation for consulting services and speaking from Bayer‚ÄSchering, Biogen‚ÄIdec, Merck‚ÄSerono, Novartis, Sanofi‚ÄAventis, and Teva Pharmaceutical Industries Ltd. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","10","Helle H Nielsen","HHN",11,TRUE,2,3,6,11,TRUE,TRUE,FALSE,0,NA,FALSE
